Vanguard Group
ALDX icon

Vanguard Group’s Aldeyra Therapeutics ALDX Stock Holding History

Vanguard Group’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$19.2M Buy
3,698,682
+106,813
+3% +$549K ﹤0.01% 2635
2025
Q3 		$18.7M Buy
3,591,869
+90,276
+3% +$471K ﹤0.01% 2655
2025
Q2 		$13.4M Sell
3,501,593
-216,425
-6% -$560K ﹤0.01% 2751
2025
Q1 		$21.4M Sell
3,718,018
-38,770
-1% -$229K ﹤0.01% 2477
2024
Q4 		$18.7M Sell
3,756,788
-3,831
-0.1% -$19.7K ﹤0.01% 2620
2024
Q3 		$20.3M Buy
3,760,619
+18,233
+0.5% +$86.8K ﹤0.01% 2587
2024
Q2 		$12.4M Sell
3,742,386
-126,693
-3% -$496K ﹤0.01% 2796
2024
Q1 		$12.7M Sell
3,869,079
-58,518
-1% -$193K ﹤0.01% 2834
2023
Q4 		$13.8M Buy
3,927,597
+740,177
+23% +$2.28M ﹤0.01% 2777
2023
Q3 		$21.3M Buy
3,187,420
+7,226
+0.2% +$53.6K ﹤0.01% 2523
2023
Q2 		$26.7M Buy
3,180,194
+681,033
+27% +$6.71M ﹤0.01% 2468
2023
Q1 		$24.8M Buy
2,499,161
+6,892
+0.3% +$48.7K ﹤0.01% 2498
2022
Q4 		$17.3M Sell
2,492,269
-23,615
-0.9% -$135K ﹤0.01% 2685
2022
Q3 		$13.4M Buy
2,515,884
+79,126
+3% +$475K ﹤0.01% 2812
2022
Q2 		$9.72M Sell
2,436,758
-524,877
-18% -$1.81M ﹤0.01% 3002
2022
Q1 		$13.2M Buy
2,961,635
+147,711
+5% +$588K ﹤0.01% 3007
2021
Q4 		$11.3M Buy
2,813,924
+86,528
+3% +$660K ﹤0.01% 3145
2021
Q3 		$23.9M Buy
2,727,396
+30,946
+1% +$284K ﹤0.01% 2757
2021
Q2 		$30.6M Buy
2,696,450
+643,955
+31% +$7.74M ﹤0.01% 2621
2021
Q1 		$24.4M Buy
2,052,495
+436,490
+27% +$5.03M ﹤0.01% 2680
2020
Q4 		$11.1M Sell
1,616,005
-35,753
-2% -$251K ﹤0.01% 2941
2020
Q3 		$12.2M Buy
1,651,758
+618,787
+60% +$4M ﹤0.01% 2687
2020
Q2 		$4.31M Sell
1,032,971
-93,671
-8% -$342K ﹤0.01% 3165
2020
Q1 		$2.78M Buy
1,126,642
+1,310
+0.1% +$5.89K ﹤0.01% 3205
2019
Q4 		$6.54M Sell
1,125,332
-3,285
-0.3% -$19K ﹤0.01% 3065
2019
Q3 		$5.95M Buy
1,128,617
+16,673
+1% +$89.8K ﹤0.01% 3073
2019
Q2 		$6.67M Buy
1,111,944
+42,869
+4% +$323K ﹤0.01% 3066
2019
Q1 		$9.65M Sell
1,069,075
-30,545
-3% -$260K ﹤0.01% 2845
2018
Q4 		$9.13M Buy
1,099,620
+151,744
+16% +$1.55M ﹤0.01% 2810
2018
Q3 		$13.1M Buy
947,876
+193,707
+26% +$1.57M ﹤0.01% 2791
2018
Q2 		$6M Buy
754,169
+56,535
+8% +$451K ﹤0.01% 3144
2018
Q1 		$5.23M Sell
697,634
-900
-0.1% -$6.83K ﹤0.01% 3136
2017
Q4 		$4.75M Buy
698,534
+227,503
+48% +$1.5M ﹤0.01% 3156
2017
Q3 		$3.39M Buy
471,031
+166,398
+55% +$869K ﹤0.01% 3249
2017
Q2 		$1.43M Buy
304,633
+9,407
+3% +$43.3K ﹤0.01% 3484
2017
Q1 		$1.48M Buy
295,226
+149,754
+103% +$771K ﹤0.01% 3470
2016
Q4 		$779K Buy
145,472
+12,586
+9% +$73.8K ﹤0.01% 3637
2016
Q3 		$1.04M Buy
132,886
+7,761
+6% +$47.4K ﹤0.01% 3562
2016
Q2 		$712K Buy
125,125
+3,718
+3% +$20.8K ﹤0.01% 3701
2016
Q1 		$508K Buy
121,407
+3,067
+3% +$14.7K ﹤0.01% 3788
2015
Q4 		$802K Buy
118,340
+11,070
+10% +$74.4K ﹤0.01% 3689
2015
Q3 		$626K Buy
107,270
+3,800
+4% +$29.7K ﹤0.01% 3785
2015
Q2 		$802K Buy
+103,470
New +$892K ﹤0.01% 3729

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group's ALDX Position: Q4 2025 in Review

Vanguard Group increased its Aldeyra Therapeutics (ALDX) stake by 3% in Q4 2025, buying an estimated $549K and bringing the position to 3,698,682 shares worth $19.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2635.

Vanguard Group first reported a position in ALDX in Q2 2015 and has held it in 43 quarters since. The position peaked at $30.6M in Q2 2021. 135 funds tracked by Wall St. Rank hold ALDX as of Q4 2025.

  • Vanguard Group held 3,698,682 shares of Aldeyra Therapeutics worth $19.2M as of Q4 2025.
  • Vanguard Group bought 106,813 Aldeyra Therapeutics shares in Q4 2025, an estimated $549K.
  • Aldeyra Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2635 holding.
  • Vanguard Group first reported a position in Aldeyra Therapeutics in Q2 2015 and has held it in 43 quarters since.
  • Vanguard Group's Aldeyra Therapeutics position peaked at $30.6M in Q2 2021.
  • 135 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.